Blennow K - Search Results

1

The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.

Pannee J, Törnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E. Pannee J, et al. Among authors: blennow k. Neurosci Lett. 2014 Jun 24;573:7-12. doi: 10.1016/j.neulet.2014.04.041. Epub 2014 May 4. Neurosci Lett. 2014. PMID: 24796810

2

Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid.

Prior R, Mönning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG, Masters CL, Beyreuther K. Prior R, et al. Among authors: blennow k. Neurosci Lett. 1991 Mar 11;124(1):69-73. doi: 10.1016/0304-3940(91)90824-d. Neurosci Lett. 1991. PMID: 1677459

3

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.

Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blennow K, et al. Acta Neurol Scand. 1990 Apr;81(4):323-6. doi: 10.1111/j.1600-0404.1990.tb01563.x. Acta Neurol Scand. 1990. PMID: 2360400

4

Clinical subgroups of the Alzheimer syndrome.

Wallin A, Blennow K. Wallin A, et al. Among authors: blennow k. Acta Neurol Scand Suppl. 1996;165:51-7. doi: 10.1111/j.1600-0404.1996.tb05872.x. Acta Neurol Scand Suppl. 1996. PMID: 8740989 Review.

5

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Andreasen N, et al. Among authors: blennow k. Neurosci Lett. 1999 Sep 24;273(1):5-8. doi: 10.1016/s0304-3940(99)00617-5. Neurosci Lett. 1999. PMID: 10505638 Clinical Trial.

6

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Hesse C, et al. Among authors: blennow k. Neurosci Lett. 2001 Jan 19;297(3):187-90. doi: 10.1016/s0304-3940(00)01697-9. Neurosci Lett. 2001. PMID: 11137759 Clinical Trial.

7

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.

Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Davidsson P, et al. Among authors: blennow k. Neurosci Lett. 2001 Mar 16;300(3):157-60. doi: 10.1016/s0304-3940(01)01586-5. Neurosci Lett. 2001. PMID: 11226635 Clinical Trial.

8

Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease.

Davidsson P, Bogdanovic N, Lannfelt L, Blennow K. Davidsson P, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2001 Jul-Aug;12(4):243-50. doi: 10.1159/000051266. Dement Geriatr Cogn Disord. 2001. PMID: 11351135

9

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process.

Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, Wallin A, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2001 Jul-Aug;12(4):257-64. doi: 10.1159/000051268. Dement Geriatr Cogn Disord. 2001. PMID: 11351137

10

Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment.

Sjögren M, Gisslén M, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Neurosci Lett. 2001 Nov 13;314(1-2):33-6. doi: 10.1016/s0304-3940(01)02285-6. Neurosci Lett. 2001. PMID: 11698140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,215 results

Search Page

Filters